Navigation Links
Biotech firm spun off from Children's Hospital raises $7 million to advance vascular treatment
Date:2/27/2012

Vascular Magnetics, the first start-up company spun off by The Children's Hospital of Philadelphia, has raised $7 million to advance development of an innovative drug delivery system using magnetically targeted nanoparticles to treat peripheral artery disease.

Vascular Magnetics, based in West Philadelphia, announced that Devon Park Bioventures, of Wayne, Pa., is the sole investor in this Series A financing agreement.

"It's exciting to see that one of our hospital's research discoveries has attracted investors to move it toward commercial development," said Philip R. Johnson, M.D., chief scientific officer and executive vice president, The Children's Hospital of Philadelphia. "This work can have multiple benefitsdirectly to patients receiving a new treatment, and also to children whose lives will be improved by future research supported by revenue generated by this technology."

Vascular Magnetics was co-founded in 2010 by Robert J. Levy, M.D., William Rashkind Endowed Chair of Pediatric Cardiology at The Children's Hospital of Philadelphia, and Richard S. Woodward, Ph.D. Levy, whose extensive laboratory research forms the basis of the proprietary drug delivery system, is the firm's founding scientist. Woodward, who has a business background in nanotechnology and polymeric coatings, is the company's president and chief operating officer. Vascular Magnetics has an exclusive license to the technology invented by Levy's cardiology research team at Children's Hospital.

Levy and Woodward were brought together through the University City Science Center's QED Proof-of-Concept Funding Program, the nation's first multi-institutional proof-of-concept program for life sciences technologies. That program partners academic scientists with business advisors to help realize the commercial potential of promising biological research.

The drug delivery system at the heart of the company's work is called vascular magnetic intervention
'/>"/>

Contact: John Ascenzi
ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2

Related biology news :

1. New project could herald cheaper and more efficient biotechnology
2. Sustainable land use strategies to support bioenergy described in Industrial Biotechnology journal
3. 2012 Biotechnology and Pharmaceuticals: Forthcoming Conferences and Exhibitions
4. BGI enters agreement with National Center for Soybean Biotechnology to re-sequence 1,008 soybean lines
5. Exploiting Trichoderma: From food security to biotechnology
6. Andromeda Biotech: A drug for type 1 diabetes
7. Biotech start-up brings DNA-sequencing to the medical market
8. FDA grants cardiotrophin-1 Orphan Drug status for acute liver failure treatment to Digna Biotech
9. The benefits of biotech
10. Biotech, food and the future
11. UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... an expansion of marine protected areas is needed to ... According to investigators from the Wildlife Conservation Society and ... on saving the largest numbers of species, often at ... difficult-to-replace ecological functions. , Many vital ecological ... that also are food for millions of people. ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... EUGENE, Ore. -- Using new optical equipment, a ... of virtual reality, monitored both their behavior and brain ... brain operates as it moves. The new research ... Scientific Instrumentation Inc. (ASI) -- should help neuroscientists around ...
... largest celebration of science and engineering, the USA ... D.C., April 28-29, 2012. For the second year, ... hands-on experiments. At Carnegie,s booth last year, visitors ... produced by our high pressure lab, touched the ...
... organisms, germ cells give rise to gametes and serve ... germ cell development is the decision to leave mitosis ... eggs and sperm. Germ cell development involves unique gene ... ensure success during fertilization and embryo development. Written ...
Cached Biology News:Worm-tracking challenge leads to new tool for brain research 2Worm-tracking challenge leads to new tool for brain research 3Carnegie partners with USA Science & Engineering Festival for second year 2Carnegie partners with USA Science & Engineering Festival for second year 3
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to a ... Market” the global orthobiologics market was valued at USD 3,754.6 ... worth USD 5,519.9million in 2019at a CAGR of 5.9% from ... 50 years and above is afflicted by bone and joint ... the year 2020. This has and will continue to increase ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
(Date:8/29/2014)... Livermore, California (PRWEB) August 29, 2014 ... Department of Energy's 2014 Hydrogen Production R&D ... photoelectrochemically -- by splitting water using sunlight. , ... Laboratory (NREL) and the University of Nevada, Las ... its work developing models of photoelectrochemical solar-hydrogen production ...
(Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... EDMONTON, April 22 /PRNewswire-FirstCall/ - Quest PharmaTech ... announce that it will receive,generous support from ... (SDT) for oncology applications., Sonodynamic Therapy ... in,Hypocrellin-based photodynamic therapy for oncology and skin ...
... $250,000 under March ... ... BMRX), a leading developer and supplier of consumer-based,finger-activated products, today announced ... personnel of Sequiam,Corporation (OTC Bulletin Board: SQUME) through a previously announced,agreement ...
... Conn., April 22 Rib-X Pharmaceuticals, Inc.,("Rib-X" ... on the,discovery and development of novel antibiotics ... that Graham Johnson,Ph.D., Chief Research Officer and ... Cambridge Healthtech Institute,s 2nd Annual "The,Challenge of ...
Cached Biology Technology:Quest PharmaTech Receives Support from National Research Council's Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer 2bioMETRX, Inc. Initiates Integration of Personnel and Assets of Sequiam Corp. 2Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institute's 2nd Annual Challenge of Antibacterial Development Conference 2
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
Request Info...
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
Biology Products: